DLBCL Clinical Trials in Shanghai, Shanghai Municipality
6 recruitingShanghai, Shanghai Municipality, China
Showing 1–6 of 6 trials
Recruiting
Phase 2Phase 3
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
DLBCL
Merck Sharp & Dohme LLC290 enrolled121 locationsNCT05139017
Recruiting
Phase 1Phase 2
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Non-Hodgkin LymphomaMantle Cell LymphomaFollicular Lymphoma+6 more
BeiGene146 enrolled29 locationsNCT05294731
Recruiting
Phase 2
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Guangzhou Lupeng Pharmaceutical Company LTD.150 enrolled41 locationsNCT07189065
Recruiting
A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL
DLBCL
Ruijin Hospital400 enrolled1 locationNCT06779435
Recruiting
Phase 2
CR-CHOP+X in Previously Untreated DEL
DLBCL
Ruijin Hospital49 enrolled1 locationNCT06701357
Recruiting
Real-World Study of DLBCL With Different Genetic Subtypes
DLBCL - Diffuse Large B Cell LymphomaLymphoma
Ruijin Hospital10,000 enrolled1 locationNCT06026488